Unknown Analyst
Welcome, everyone. My name is [ Tai Pavumi ], and I’m welcoming you to the 44th JPMorgan Healthcare Conference. Our next presenting company is Protara Therapeutics. Protara is a clinical stage biotechnology company that’s developing transformative therapies for people with rare cancer diseases. And presenting today is CEO, Jesse Shefferman. Please help me welcoming to the stage.
Jesse Shefferman
Co-founder, CEO, President & Director
Thank you. Thanks, [ Tai ]. Thank you to the JPMorgan team for having us. I’m looking forward to talking through the Protara story. Quick forward-looking statements. So as [ Tai ] 1said, Protara is a clinical stage company focused on oncology and in rare disease. In oncology, our primary focus is in non-muscle invasive bladder cancer, where we have 2 programs in late-stage development, 2 registrational studies in BCG-Unresponsive patients and in BCG-Naïve patients.
On the rare disease side, we have 2 products in clinical development. IV Choline Chloride is a phospholipid substrate replacement therapy for patients that are on parenteral support. That program is in Phase III with a PK-based endpoint. And we also have our lymphatic malformations program, TARA-002 for macrocystic and macrocystic-dominant mixed cystic lesions.
Just gives a sense of our portfolio. For a company of our size, we have a lot of ambition, and this is represented by the various programs that we have in late-stage development. In non-muscle invasive bladder cancer, our ADVANCED-2 study is a single-arm open-label study looking at BCG-Unresponsive patients with carcinoma in situ. There, we are significantly well enrolled in a registrational study that we anticipate will complete enrollment before the end of 2026.
We also
